Astellas Pharma Inc. – Product Pipeline Review

Global Markets Direct’s, ‘Astellas Pharma Inc. – Product Pipeline Review – 2016’, provides an overview of the Astellas Pharma Inc.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Astellas Pharma Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of Astellas Pharma Inc.

The report provides overview of Astellas Pharma Inc. including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses Astellas Pharma Inc.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features Astellas Pharma Inc.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate Astellas Pharma Inc.’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Astellas Pharma Inc.

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Astellas Pharma Inc.’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 6

Astellas Pharma Inc. Snapshot 7

Astellas Pharma Inc. Overview 7

Key Information 7

Key Facts 7

Astellas Pharma Inc. - Research and Development Overview 8

Key Therapeutic Areas 8

Astellas Pharma Inc. - Pipeline Review 16

Pipeline Products by Stage of Development 16

Pipeline Products - Monotherapy 17

Pipeline Products - Combination Treatment Modalities 18

Pipeline Products - Partnered Products 19

Pipeline Products - Out-Licensed Products 22

Astellas Pharma Inc. - Pipeline Products Glance 24

Astellas Pharma Inc. - Late Stage Pipeline Products 24

Astellas Pharma Inc. - Clinical Stage Pipeline Products 27

Astellas Pharma Inc. - Early Stage Pipeline Products 29

Astellas Pharma Inc. - Drug Profiles 33

linaclotide 33

solifenacin succinate 36

tacrolimus ER 38

(ipragliflozin + sitagliptin phosphate) 39

(mirabegron + solifenacin succinate) 40

amenamevir 42

ASP-0113 43

bendamustine hydrochloride 44

degarelix acetate 47

enzalutamide 49

evolocumab 53

fidaxomicin 56

gilteritinib fumarate 59

mirabegron ER 61

naquotinib mesylate 63

peficitinib hydrobromide 64

quetiapine fumarate ER 66

romosozumab 67

roxadustat 69

AGS-16C3F 72

ASP-1707 73

ASP-3662 74

ASP-7962 75

ASP-8232 76

erlotinib hydrochloride 77

FG-2216 80

ipragliflozin 82

linsitinib 86

MA09-hRPE 89

regadenoson 91

blinatumomab 93

AGS-67E 97

ASG-15ME 99

ASP-0819 100

ASP-2205 101

ASP-2905 102

ASP-4132 103

ASP-4345 104

ASP-5094 105

ASP-5878 106

ASP-6282 107

ASP-6294 108

ASP-7266 109

ASP-7398 110

ASP-8062 111

enfortumab vedotin 112

OSI-930 113

AS-1069562 114

AS-1669058 115

AS-1940477 116

AS-2034178 117

AS-2077715 118

AS-2444697 119

AS-2521780 120

AS-2575959 121

AS-2715348 122

AS-2795440 123

AS-288640100 124

ASP-1017 125

ASP-1645 126

ASP-3258 127

ASP-5736 128

ASP-6537 129

ASP-7663 130

ASP-9133 131

ASP-9726 132

FK-886 133

Gene Therapy to Activate mVChR1 for Retinits Pigmentosa 135

KB-425796C 136

Monoclonal Antibody Conjugates for Oncology 137

OSI-296 138

Small Molecule 2 for Epilepsy 140

Small Molecule 3 for Epilepsy 141

Small Molecule 4 for Epilepsy 142

Small Molecule for Epilepsy 143

Small Molecule to Block N-type Calcium and hERG Potassium Channels for Neuropathic Pain 144

Small Molecule to Inhibit 17-Beta-HSD for Castration-Resistant Prostate Cancer 145

Small Molecule to Inhibit JAK3 for Heart Transplantation 146

Small Molecule to Inhibit PDE10A for Schizophrenia 147

Small Molecule to Inhibit TAK1 for Ovarian Cancer 148

Small Molecules to Agonize GPR119 Receptor for Type 2 Diabetes 149

Small Molecules to Inhibit 5-HT2B and 5-HT7 Receptors for IBS and Migraine 150

Small Molecules to Inhibit DAAO for Cognitive Disorders 151

Small Molecules to Inhibit RANKL for Osteoclastogenesis 152

Stem Cell Therapy for Autoimmune Diseases 153

Stem Cell Therapy for Corneal Blindness 154

Stem Cell Therapy for Glaucoma 155

Stem Cell Therapy for Ophthalmic Disorders 156

UMN-0901 157

AS-1468240 158

Drugs for Pancreatic Cancer 159

KB-425796A 160

Monoclonal Antibodies for Oncology 161

Small Molecules for Non-Neuromuscular and Neuromuscular Disorders 162

Small Molecules to Activate Troponin for Non-Neuromuscular and Neuromuscular Disorders 163

Small Molecules to Inhibit ACK1 for Oncology 164

Astellas Pharma Inc. - Pipeline Analysis 165

Astellas Pharma Inc. - Pipeline Products by Target 165

Astellas Pharma Inc. - Pipeline Products by Route of Administration 175

Astellas Pharma Inc. - Pipeline Products by Molecule Type 176

Astellas Pharma Inc. - Pipeline Products by Mechanism of Action 177

Astellas Pharma Inc. - Recent Pipeline Updates 184

Astellas Pharma Inc. - Dormant Projects 256

Astellas Pharma Inc. - Discontinued Pipeline Products 258

Discontinued Pipeline Product Profiles 260

Astellas Pharma Inc. - Company Statement 268

Astellas Pharma Inc. - Locations And Subsidiaries 269

Head Office 269

Other Locations & Subsidiaries 269

Astellas Pharma Inc. - Key Manufacturing Facilities 275

Appendix 276

Methodology 276

Coverage 276

Secondary Research 276

Primary Research 276

Expert Panel Validation 276

Contact Us 276

Disclaimer 277

List of Tables

List of Tables

Astellas Pharma Inc., Key Information 15

Astellas Pharma Inc., Key Facts 15

Astellas Pharma Inc. – Pipeline by Indication, 2016 17

Astellas Pharma Inc. – Pipeline by Stage of Development, 2016 24

Astellas Pharma Inc. – Monotherapy Products in Pipeline, 2016 25

Astellas Pharma Inc. – Combination Treatment Modalities in Pipeline, 2016 26

Astellas Pharma Inc. – Partnered Products in Pipeline, 2016 27

Astellas Pharma Inc. – Partnered Products/ Combination Treatment Modalities, 2016 28

Astellas Pharma Inc. – Out-Licensed Products in Pipeline, 2016 30

Astellas Pharma Inc. – Out-Licensed Products/ Combination Treatment Modalities, 2016 31

Astellas Pharma Inc. – Pre-Registration, 2016 32

Astellas Pharma Inc. – Filing rejected/Withdrawn, 2016 33

Astellas Pharma Inc. – Phase III, 2016 34

Astellas Pharma Inc. – Phase II, 2016 35

Astellas Pharma Inc. – Phase I, 2016 36

Astellas Pharma Inc. – IND/CTA Filed, 2016 37

Astellas Pharma Inc. – Preclinical, 2016 38

Astellas Pharma Inc. – Discovery, 2016 40

Astellas Pharma Inc. – Pipeline by Target, 2016 173

Astellas Pharma Inc. – Pipeline by Route of Administration, 2016 183

Astellas Pharma Inc. – Pipeline by Molecule Type, 2016 184

Astellas Pharma Inc. – Pipeline Products by Mechanism of Action, 2016 185

Astellas Pharma Inc. – Recent Pipeline Updates, 2016 192

Astellas Pharma Inc. – Dormant Developmental Projects,2016 264

Astellas Pharma Inc. – Discontinued Pipeline Products, 2016 266

Astellas Pharma Inc., Other Locations 277

Astellas Pharma Inc., Subsidiaries 278

Astellas Pharma Inc., Key Manufacturing Facilities 283

List of Figures

List of Figures

Astellas Pharma Inc. – Pipeline by Top 10 Indication, 2016 17

Astellas Pharma Inc. – Pipeline by Stage of Development, 2016 24

Astellas Pharma Inc. – Monotherapy Products in Pipeline, 2016 25

Astellas Pharma Inc. – Partnered Products in Pipeline, 2016 27

Astellas Pharma Inc. – Out-Licensed Products in Pipeline, 2016 30

Astellas Pharma Inc. – Pipeline by Top 10 Target, 2016 173

Astellas Pharma Inc. – Pipeline by Route of Administration, 2016 183

Astellas Pharma Inc. – Pipeline by Molecule Type, 2016 184

Astellas Pharma Inc. – Pipeline Products by Top 10 Mechanism of Action, 2016 185

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports